Shares of Hospira (HSP) tumbled 2.81% to close the trading session on Aug 19 at $53.92 per share, following the company’s decision to file a lawsuit against the FDA over approvals granted to generic ...
Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Hospira Inc. is suing fellow pharma manufacturer Akorn Inc ...
Add Yahoo as a preferred source to see more of our stories on Google. By Brendan Pierson (Reuters) - A federal judge has issued a temporary restraining order against the U.S. Food and Drug ...
Dexmedetomidine HCl in 0.9% NaCl; 4mcg/mL; soln for IV infusion. Precedex (dexmedetomidine hydrochloride) injection 200 mcg/2 mL (100 mcg/mL) is clear and colorless. The strength is based on the ...
Hospira's reprieve from generic Precedex competition was short-lived. The U.S. district court that temporarily stopped Precedex generics has now decided to let the copycats roll. And that could mean ...
WOODCLIFF LAKE, N.J., Sept. 8, 2014 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. today announced that it has resumed shipping dexmedetomidine hydrochloride (HCl) injection, EQ 100 mcg base/mL, ...
Dr. Reddy’ is offering dexmedetomidine hydrochloride in 0.9% sodium chloride injection. The product is the generic of Hospira’s Precedex (dexmedetomidine hydrochloride) in 0.9% Sodium Chloride ...
Drug maker Hospira Inc. took the unusual step of filing a lawsuit to challenge the U.S. Food and Drug Administration's approval this week of generic copies of the company's best-selling product, the ...
Milla Pharmaceuticals has received the Food and Drug Administration’s blessing for generic Precedex (dexmedetomidine hydrochloride injection) 4 mcg/ml in 50 ml and 100 ml. The injection is indicated ...
The FDA has approved Precedex (dexmedetomidine HCl, from Hospira) injection for the sedation of non-intubated patients prior to and/or during surgical and other procedures. This approval is based on ...
Shares of Hospira ( HSP) tumbled 2.81% to close the trading session on Aug 19 at $53.92 per share, following the company's decision to file a lawsuit against the FDA over approvals granted to generic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results